pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Opdivo · news · pharmadog
← back to Opdivo
News mentioning Opdivo
43
stories
1d
Akeso, Summit cancer drug confirms lung cancer survival benefit
biopharma dive
1d
Replimune’s melanoma drug would have been rejected again if not for senior CBER official
biospace
2d
Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial fails
biospace
11d
Capricor, Replimune reviews signal FDA’s return to reliability but every application will stand alone
biospace
18d
AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer
biopharma dive
25d
BMS picks Texas for new $2.3B manufacturing campus
biospace
29d
Replimune rebounds to win FDA approval of melanoma drug
biopharma dive
29d
Third time’s the charm for Replimune as melanoma drug earns FDA greenlight
biospace
29d
FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma
fda press
Aug 5, 26
No deal between AstraZeneca and BMS, senior source insists: Reuters
biospace
Aug 5, 26
Chaotic adcomms threaten to derail FDA’s bid to renew trust after Makary, Prasad
biospace
Aug 5, 26
Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
biospace
Aug 4, 26
As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger
biospace
Aug 3, 26
An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.
biopharma dive
Aug 3, 26
‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
biospace
Aug 3, 26
Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
fiercebiotech
Jul 30, 26
Replimune overcomes ‘messy data’ to secure positive adcomm vote for melanoma therapy
biospace
Jul 30, 26
Replimune melanoma drug wins support of FDA panel
biopharma dive
Jul 30, 26
Replimune’s twice-rejected melanoma drug prevails in FDA adcomm
fiercebiotech
Jul 30, 26
BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays
biospace
Jul 28, 26
STAT+: FDA staff reiterate concerns about Replimune skin cancer treatment
stat
Jul 28, 26
FDA says Replimune’s melanoma data package is ‘not interpretable,’ setting up tough adcomm
biospace
Jul 27, 26
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
biospace
Jul 23, 26
Scancell to go public after winning reverse merger bid for troubled Neuphoria
fiercebiotech
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive
Jun 15, 26
Medicare drug price rule may target under-the-skin Keytruda and Opdivo
biopharma dive
May 31, 26
Ultra-low doses could bring costly cancer treatments to more patients in poorer countries
stat
May 29, 26
Replimune takes third swing at cancer drug approval following ‘productive’ FDA talks
biopharma dive
May 11, 26
Biotech layoffs are easing, but is the worst over?
biopharma dive
May 10, 26
Nivolumab Plus SOC Therapy Shows Encouraging Disease Control in Grade Group 5 Prostate Cancer
onclive
← prev
page 1 of 2
next →
